Ola Landgren

43.2k total citations · 2 hit papers
504 papers, 17.6k citations indexed

About

Ola Landgren is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ola Landgren has authored 504 papers receiving a total of 17.6k indexed citations (citations by other indexed papers that have themselves been cited), including 343 papers in Hematology, 189 papers in Molecular Biology and 169 papers in Oncology. Recurrent topics in Ola Landgren's work include Multiple Myeloma Research and Treatments (316 papers), Protein Degradation and Inhibitors (106 papers) and Chronic Lymphocytic Leukemia Research (97 papers). Ola Landgren is often cited by papers focused on Multiple Myeloma Research and Treatments (316 papers), Protein Degradation and Inhibitors (106 papers) and Chronic Lymphocytic Leukemia Research (97 papers). Ola Landgren collaborates with scholars based in United States, Sweden and Iceland. Ola Landgren's co-authors include Sigurður Y. Kristinsson, Magnus Björkholm, Lynn R. Goldin, Ingemar Turesson, Ruth M. Pfeiffer, S. Vincent Rajkumar, Eric A. Engels, Gloria Gridley, Neha Korde and Åsa Rangert Derolf and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Ola Landgren

476 papers receiving 17.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

2009 743 citations Ola Landgren, Robert A. Kyle et al. Blood profile →
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

2020 289 citations Meletios Α. Dimopoulos, María‐Victoria Mateos et al. profile →

Peers

Countries citing papers authored by Ola Landgren

Since Specialization

Citations

This map shows the geographic impact of Ola Landgren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ola Landgren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ola Landgren more than expected).

Fields of papers citing papers by Ola Landgren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ola Landgren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ola Landgren. The network helps show where Ola Landgren may publish in the future.

Co-authorship network of co-authors of Ola Landgren

This figure shows the co-authorship network connecting the top 25 collaborators of Ola Landgren. A scholar is included among the top collaborators of Ola Landgren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ola Landgren. Ola Landgren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma 2024 ·Clinical Cancer Research ·Dickran Kazandjian, Benjamin Diamond, (unknown), (unknown), Romanos Sklavenitis‐Pistofidis, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Kylee Maclachlan, Ryan M. Young, Saad Z. Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Neha Korde, Gareth J. Morgan, Francesco Maura, Ola Landgren	5
2	Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap 2024 ·Blood Cancer Discovery ·Ola Landgren, Sean M. Devlin	3
3	Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma 2023 ·Clinical Cancer Research ·Monika Chojnacka, Benjamin Diamond, Bachisio Ziccheddu, Even H. Rustad, Kylee Maclachlan, (unknown), Eileen M. Boyle, Patrick Blaney, Saad Z. Usmani, Gareth J. Morgan, Ola Landgren, Francesco Maura	1
4	Single Cell Analysis of Bone Marrow Stromal Cells Shows That a Pro-Inflammatory and Stress Response Together with Polarized Differentiation of Stromal Elements Characterize the Bone Marrow Microenvironment during Multiple Myeloma Development 2023 ·Blood ·Hussein Ghamlouch, (unknown), Patrick Blaney, Eileen M. Boyle, Yubao Wang, Liming Hou, Ola Landgren, Francesco Maura, Aristotelis Tsirigos, Gareth J. Morgan, Faith E. Davies	1
5	Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events 2021 ·Hematology ·Ola Landgren	17
6	A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study 2021 ·Blood ·Urvi A. Shah, (unknown), (unknown), (unknown), (unknown), Andriy Derkach, Sham Mailankody, Neha Korde, Carlyn Tan, Malin Hultcrantz, Sydney X. Lu, (unknown), Hani Hassoun, Anita D’Souza, Sergio Giralt, Neil M. Iyengar, Ola Landgren, Marcel R.M. van den Brink, Alexander M. Lesokhin	0
7	Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma 2020 ·Clinical Cancer Research ·Francesco Maura, Ola Landgren, Gareth J. Morgan	15
8	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy 2019 ·Cancer Immunology Research ·Eric L. Smith, Sham Mailankody, Mette Stæhr, Xiuyan Wang, Brigitte Sénéchal, Terence J. Purdon, Anthony F. Daniyan, Mark B. Geyer, Aaron D. Goldberg, Elena Mead, Bianca Santomasso, Jonathan Landa, Andreas Rimner, Isabelle Rivière, Ola Landgren, Renier J. Brentjens	67
9	Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation 2017 ·Molecular Cancer Therapeutics ·John K. Simmons, Aleksandra M. Michalowski, (unknown), Wendy Dubois, Jyoti D. Patel, Ke Zhang, Joy Gary, Shuling Zhang, Snehal Gaikwad, (unknown), Nicholas Watson, (unknown), Jin‐Qiu Chen, W. Michael Kuehl, Maxwell P. Lee, Adriana Zingone, Ola Landgren, Peter Ordentlich, Jing Huang, Beverly A. Mock	27
10	Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non- MMSET Myeloma Patients 2016 ·Clinical Cancer Research ·Shijie Wu, Ruth M. Pfeiffer, Inhye E. Ahn, Sham Mailankody, Pieter Sonneveld, Mark van Duin, Nikhil Munshi, Brian A. Walker, Gareth J. Morgan, Ola Landgren	12
11	Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals 2016 ·Cancer Research ·Jonathan N. Hofmann, Brenda M. Birmann, Lauren R. Teras, Ruth M. Pfeiffer, Ye Wang, Demetrius Albanes, Dalsu Baris, Graham A. Colditz, Anneclaire J. De Roos, Graham G. Giles, H. Dean Hosgood, Qing Lan, Ola Landgren, Linda M. Liao, Nathaniel Rothman, Stephanie J. Weinstein, Michaël Pollak, Marian L. Neuhouser, Mark P. Purdue	27
12	Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma 2016 ·Clinical Cancer Research ·Mattias Carlsten, Neha Korde, Ritesh R. Kotecha, Robert Reger, (unknown), Dickran Kazandjian, Ola Landgren, Richard Childs	134
13	Smoldering multiple myeloma 2015 ·Blood ·S. Vincent Rajkumar, Ola Landgren, María‐Victoria Mateos	179
14	Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Systematic Review 2014 ·Cancer Epidemiology Biomarkers & Prevention ·Charlene M. McShane, Liam Murray, Ola Landgren, Michael O’Rorke, Neha Korde, Andrew T. Kunzmann, Roshidi Ismail, Lesley Anderson	45
15	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. 2014 ·UCL Discovery (University College London) ·Meletios Α. Dimopoulos, Efstathios Kastritis, Roger G. Owen, Robert A. Kyle, Ola Landgren, (unknown), Xavier Leleu, Nikhil C. Munshi, Kenneth C. Anderson, (unknown), Irene M. Ghobrial, (unknown), David G. Maloney, (unknown), Ranjana H. Advani, Morie A. Gertz, (unknown), Sheeba K. Thomas, (unknown), (unknown), (unknown), (unknown), Steven P. Treon, (unknown), (unknown)	0
16	Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms 2011 ·Journal of Clinical Oncology ·Magnus Björkholm, Åsa Rangert Derolf, Malin Hultcrantz, Sigurður Y. Kristinsson, Charlotta Ekstrand, Lynn R. Goldin, Björn Andréasson, Gunnar Birgegård, Olle Linder, Claes Malm, Berit Markevärn, Lars Nilsson, Jan Samuelsson, Fredrik Granath, Ola Landgren	174
17	Circulating Serum Free Light Chains As Predictive Markers of AIDS-Related Lymphoma 2010 ·Journal of Clinical Oncology ·Ola Landgren, James J. Goedert, Charles S. Rabkin, Wyndham H. Wilson, Kieron Dunleavy, Robert A. Kyle, Jerry A. Katzmann, S. Vincent Rajkumar, Eric A. Engels	80
18	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study breakdown → 2009 ·Blood ·Ola Landgren, Robert A. Kyle, Ruth M. Pfeiffer, Jerry A. Katzmann, Neil E. Caporaso, Richard B. Hayes, Angela Dispenzieri, Shaji Kumar, Raynell Clark, Dalsu Baris, Robert N. Hoover, S. Vincent Rajkumar	743
19	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden 2009 ·Blood ·Ola Landgren, Sigurður Y. Kristinsson, Lynn R. Goldin, Neil E. Caporaso, Cecilie Blimark, Ulf‐Henrik Mellqvist, Anders Wåhlin, Magnus Björkholm, Ingemar Turesson	101
20	Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden 2008 ·Blood ·Ola Landgren, Lynn R. Goldin, Sigurður Y. Kristinsson, (unknown), Jan Samuelsson, Magnus Björkholm	162

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact